PSNL Insider Trading

Insider Ownership Percentage: 4.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $37,446.97

Personalis Insider Trading History Chart

This chart shows the insider buying and selling history at Personalis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

Personalis Share Price & Price History

Current Price: $5.36
Price Change: Price Increase of +0.35 (6.99%)
As of 01/30/2025 05:00 PM ET

This chart shows the closing price history over time for PSNL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MarAprMayJunJulAugSepOctNovDecJan$5.01Closing price on 01/29/25:

SEC Filings (Institutional Ownership Changes) for Personalis (NASDAQ:PSNL)

61.91% of Personalis stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PSNL by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$1.73Mbought$459ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5M$0$5MTotal InflowsTotal Outflows
Personalis logo
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.
Read More on Personalis

Today's Range

Now: $5.36
Low: $5.07
High: $5.42

50 Day Range

MA: $4.93
Low: $3.38
High: $6.64

52 Week Range

Now: $5.36
Low: $1.12
High: $7.20

Volume

606,443 shs

Average Volume

1,211,985 shs

Market Capitalization

$378.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.75

Who are the company insiders with the largest holdings of Personalis?

Personalis' top insider investors include:
  1. Aaron Tachibana (CFO)
  2. Christopher M Hall (CEO)
  3. Richard Chen (EVP)
  4. Richard Chen (Insider)
  5. Stephen Michael Moore (General Counsel)
  6. Stephen Michael Moore (SVP)
Learn More about top insider investors at Personalis.

Who are the major institutional investors of Personalis?

Personalis' top institutional shareholders include:
  1. Sumitomo Mitsui Trust Group Inc. — 1.04%
  2. abrdn plc — 0.42%
  3. Green Alpha Advisors LLC — 0.06%
  4. China Universal Asset Management Co. Ltd. — 0.02%
  5. SG Americas Securities LLC — 0.02%
Learn More about top institutional investors of Personalis stock.

Which institutional investors are selling Personalis stock?

During the previous quarter, PSNL stock was sold by these institutional investors:
  1. Sumitomo Mitsui Trust Group Inc.
  2. Green Alpha Advisors LLC
During the previous year, company insiders that have sold Personalis company stock include:
  1. Aaron Tachibana (CFO)
  2. Christopher M Hall (CEO)
  3. Richard Chen (EVP)
Learn More investors selling Personalis stock.

Which institutional investors are buying Personalis stock?

Within the last quarter, PSNL stock was acquired by institutional investors including:
  1. abrdn plc
  2. China Universal Asset Management Co. Ltd.
  3. SG Americas Securities LLC